Revlimid and Rituxan Combo 'Another Potential Option' For Patients With Mantle Cell Lymphoma
“We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn. Hear more about this treatment in his interview with CURE®.
In a recent interview with CURE®, Dr. Ian Flinn, director of lymphoma research at Sarah Cannon Research Institute, discussed the benefits of Revlimid (lenalidomide) in combination with Rituxan (rituximab) in patients with mantle cell lymphoma.
Transcription:
Another potential option for many patients is the drug lenalidomide in combination with Rituxan, some patients have a more inlet form of mantle cell lymphoma and this is a very reasonable combination for that patient group as well as others. Lenalidomide is a cousin of a drug thalidomide.
Thalidomide was a drug that unfortunately has a terrible side effect, that it caused birth defects. For that reason, it’s a terrible drug but it has great anti-cancer properties where it’s very effective. We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about.
